322 related articles for article (PubMed ID: 10975555)
1. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment.
Cornelison TL
Curr Opin Oncol; 2000 Sep; 12(5):466-73. PubMed ID: 10975555
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus vaccines for the prevention and treatment of cervical cancer.
Tomson TT; Roden RB; Wu TC
Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945
[TBL] [Abstract][Full Text] [Related]
4. Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers.
Ling M; Kanayama M; Roden R; Wu TC
J Biomed Sci; 2000; 7(5):341-56. PubMed ID: 10971133
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccines for cervical cancer: from bench to bedside.
Hung CF; Monie A; Alvarez RD; Wu TC
Exp Mol Med; 2007 Dec; 39(6):679-89. PubMed ID: 18160838
[TBL] [Abstract][Full Text] [Related]
6. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus vaccines for cervical cancer.
Murakami M; Gurski KJ; Steller MA
J Immunother; 1999 May; 22(3):212-8. PubMed ID: 10335480
[TBL] [Abstract][Full Text] [Related]
8. Prospects for therapeutic HPV vaccines.
Trimble CL
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S249-50. PubMed ID: 16419216
[No Abstract] [Full Text] [Related]
9. Towards vaccines against human papillomavirus type-16 genital infections.
Cason J; Khan SA; Best JM
Vaccine; 1993; 11(6):603-11. PubMed ID: 8391738
[TBL] [Abstract][Full Text] [Related]
10. Overview of vaccinology with special reference to papillomavirus vaccines.
Hilleman MR
J Clin Virol; 2000 Oct; 19(1-2):79-90. PubMed ID: 11091151
[TBL] [Abstract][Full Text] [Related]
11. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.
Lamikanra A; Pan ZK; Isaacs SN; Wu TC; Paterson Y
J Virol; 2001 Oct; 75(20):9654-64. PubMed ID: 11559797
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
13. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection.
Stanley MA
Expert Rev Vaccines; 2003 Jun; 2(3):381-9. PubMed ID: 12903803
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus vaccines.
Stanley MA
Curr Opin Mol Ther; 2002 Feb; 4(1):15-22. PubMed ID: 11883690
[TBL] [Abstract][Full Text] [Related]
15. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
16. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
17. [Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].
Huang W; Tian HW; Ren J; Fan JT; Zhao L; Bian T; Lu ZH; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):240-3. PubMed ID: 16261206
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
[TBL] [Abstract][Full Text] [Related]
19. Immunization against human papillomavirus infection and associated neoplasia.
Osen W; Jochmus I; Müller M; Gissmann L
J Clin Virol; 2000 Oct; 19(1-2):75-8. PubMed ID: 11091150
[TBL] [Abstract][Full Text] [Related]
20. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]